In late February 2026, Ligand Pharmaceuticals reported past fourth-quarter 2025 revenue of US$59.67 million and full-year 2025 revenue of US$268.09 million, moving from a prior-year net loss to net ...

As of Thursday, February 26, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 5.99%, which has investors questioning if this is right time to buy.

Q4 2025 Management View Todd Davis, CEO, highlighted that "2025 was a defining year for Ligand. We delivered exceptional financial performance with full-year adjusted EPS exceeding our original 2025 ...

Robust financial performance driven by full year 2025 royalty revenue growth of 48%Reiterating 2026 financial guidance of $245-$285 million in ...

Wall Street remains bullish on the stock. All eight analysts covering Ligand rate it a buy, with a consensus price target of $244.33 implying 29% upside from the current $189 share price. The company ...

Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline.

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.46 per share. The drugmaker posted revenue of $59.7 million in the period, which also beat Street ...